The Immunotherapy Series, Part Three: Policy and the FDA

Immunotherapy and Policy. How can the FDA evolve to help advance and support novel approaches to medicine? How does the field of immune-driven diagnostics serve as a case in point for the need for evolution in existing regulatory frameworks?

Special guests:

Meghan Gutierrez

Chief Executive Officer

Lymphoma Research Foundation

Leo David Wang, M.D., Ph.D.

Assistant Professor, Department of Immuno-Oncology

Assistant Professor, Department of Pediatrics

City Of Hope

This series is brought to you ad-free by Adaptive Biotechnologies

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.